Meet Eduard Ayuso from DINAMIQS
Each month, we gather partners from the MAGIC project to discuss aspects in relation to gene therapies. Readers will learn who the people behind the MAGIC Project are, why we are committed to advancing gene therapies, and how our roles in MAGIC are crucial for achieving better health outcomes for people living with muscular dystrophies
In brief words, please let us know who you are individually and on behalf of which project partner organization.
My name is Eduard Ayuso, and I am the Chief Technology Officer at Siegfried DINAMIQS. With over 20 years of experience in both academia and industry, I have worked on in vivo gene transfer, viral vector development, and analytics. I previously led a research team at INSERM and the Translational Vector Core at the University of Nantes (France). Having been on both the academic and industrial sides, I understand the challenges of translating research into scalable manufacturing. As part of the MAGIC consortium, our company DINAMIQS focuses on AAV production and quality control to support the development of gene therapies for muscular dystrophies.
Why are you participating in the MAGIC project? How can your perspectives complement the MAGIC project goal to accelerate the development of genetic therapies for muscular dystrophies?
As a very dynamic company, we bring both fresh innovation and deep expertise to the MAGIC project. Our team includes highly skilled scientists with 100+ publications in the field, as well as a GMP team with extensive commercial experience, ensuring that we understand what it takes to move from small-scale research to large-scale, GMP-compliant production. We specialize in optimizing LV and AAV production processes and have the analytical expertise to ensure the highest quality standards. By supporting and collaborating with our consortium partners from the earliest stages, we can proactively address manufacturing challenges, streamline scale-up, and ensure that promising therapies are not only scientifically groundbreaking but also manufacturable at a quality and cost that make them viable for patients. Together, we can turn cutting-edge research into real-world treatments that have a lasting impact.
What have been the current challenges regarding the development of genetic therapies for muscular dystrophies for you?
A major challenge in developing genetic therapies for muscular dystrophies is translating promising research into scalable, high-quality manufacturing processes that meet regulatory and commercial standards. AAV production is complex, requiring precise control over yield, purity, and potency to ensure both therapeutic efficacy and patient safety. Additionally, manufacturing costs remain a critical barrier to accessibility. Many gene therapy candidates struggle to move beyond early-stage development due to these hurdles. By optimizing scalable production strategies early on, we aim to make high-quality gene therapies more reliable, efficient, and ultimately more affordable for patients.
What are the main outcomes (direct results) you expect from the project?
We expect to develop an optimized, scalable AAV production process for novel muscle-targeted AAV serotypes that aligns with the unique needs of a gene therapy for muscular dystrophy. By working closely with the other consortium partners, we aim to create manufacturing solutions that not only support this project but also establish a foundation for future gene therapy production. Additionally, we anticipate advancing innovative technologies that enhance production efficiency, quality, and yield—ultimately contributing to making therapies more accessible.
What are the expected impacts on your organisation from participating in the project?
Participating in MAGIC allows us to further refine our expertise in AAV manufacturing and strengthen our position as a leader in advanced therapy production. Collaborating with top-tier scientists and innovators gives us valuable insights into the latest developments in gene therapy, helping us stay at the forefront of the field. Most importantly, by developing high-reliability, scalable production strategies, we contribute to making these life-changing therapies a reality for patients who need them most.
